Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Approved

PharmaTherCSE: PHRM

2 Drug Candidates1 Trial

Canadian specialty pharmaceutical company focused on ketamine-based therapies for psychiatric and neurological conditions. KETARX™ (racemic ketamine IV) received FDA approval in August 2025, making PharmaTher one of the first Canadian companies to achieve US regulatory approval for a ketamine product. Also developing KETABET, a proprietary combination of ketamine and betaine.

Drug Pipeline

2

KETARX™

Ketamine
Approved

FDA approved August 11, 2025. Racemic ketamine IV formulation for clinical psychiatric and neurological applications.

KETABET

Ketamine
Pre-clinical

Proprietary combination of ketamine and betaine under investigation for enhanced therapeutic outcomes.

Quick Facts

Type
Public Biotech
Founded
2019
Ticker
CSE: PHRM
Lead Stage
Approved
Website
Visit

Sponsored Trials

1
Temporarily not availableII

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease

Start Date
Compounds
Ketamine, Placebo